Planning feasibility of extremely hypofractionated prostate radiotherapy on a 1.5?T magnetic resonance imaging guided linear accelerator.

ABSTRACT:

Background and purpose

Recently, intermediate and high-risk prostate cancer patients have been treated in a multicenter phase II trial with extremely hypofractionated prostate radiotherapy (hypo-FLAME trial). The purpose of the current study was to investigate whether a 1.5?T magnetic resonance imaging guided linear accelerator (MRI-linac) could achieve complex dose distributions of a quality similar to conventional linac state-of-the-art prostate treatments.

Materials and methods

The clinically delivered treatment plans of 20 hypo-FLAME patients (volumetric modulated arc therapy, 10?MV, 5?mm leaf width) were included. Prescribed dose to the prostate was 5?×?7?Gy, with a focal tumor boost up to 5?×?10?Gy. MRI-linac treatment plans (intensity modulated radiotherapy, 7?MV, 7?mm leaf width, fixed collimator angle and 1.5?T magnetic field) were calculated. Dose distributions were compared.

Results

In both conventional and MRI-linac treatment plans, the V35Gy to the whole prostate was >99% in all patients. Mean dose to the gross tumor volume was 45?Gy for conventional and 44?Gy for MRI-linac plans, respectively. Organ at risk doses were met in the majority of plans, except for a rectal V35Gy constraint, which was exceeded in one patient, by 1?cc, for both modalities. The bladder V32Gy and V28Gy constraints were exceeded in two and one patient respectively, for both modalities.

Conclusion

Planning of stereotactic radiotherapy with focal ablative boosting in prostate cancer on a high field MRI-linac is feasible with the current MRI-linac properties, without deterioration of plan quality compared to conventional treatments.

SUBMITTER: den Hartogh MD 

PROVIDER: S-EPMC7807729 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature